| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT01802489 | Optic Neuritis|Multiple Sclerosis | Drug: Amiloride|Drug: Placebo | University of Oxford|Multiple Sclerosis Society of Great Britain and Northern Ireland | Phase 2 | 2013-02-01 | 2015-02-03 |
| NCT02122731 | Hypertension|Type 2 Diabetes Mellitus|Microalbuminuria | Drug: Amiloride | Ib Abildgaard Jacobsen|Odense University Hospital | Phase 4 | 2010-11-01 | 2014-04-23 |
| NCT00709137 | Hypertension | Drug: spironolactone|Drug: amiloride | VA Salt Lake City Health Care System | | 2008-10-01 | 2014-05-27 |
| NCT03031496 | Hypertension | Drug: GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|Drug: Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) | GlaxoSmithKline | Phase 1 | 2017-03-01 | 2017-03-14 |
| NCT02522650 | Proteinuria | Drug: Amiloride|Drug: Triamterene | Georgetown University | Phase 4 | 2013-07-01 | 2016-11-18 |
| NCT01308983 | Prehypertension | Drug: Amiloride | Augusta University | Phase 4 | 2010-09-01 | 2012-10-22 |
| NCT01879527 | Optic; Neuritis, With Demyelination | Drug: Amiloride hydrochlorothiazide|Drug: Sugar pill | Medical University of Vienna | Phase 2 | 2014-03-01 | 2015-05-08 |
| NCT01733680 | ADHD | Drug: amiloride|Behavioral: Behavioral | State University of New York - Upstate Medical University | Early Phase 1 | 2012-09-01 | 2014-11-19 |
| NCT00274391 | Cystic Fibrosis | Drug: 7% NaCl|Drug: Amiloride HCl | University of North Carolina|Cystic Fibrosis Foundation Therapeutics|University of North Carolina, Chapel Hill | Phase 2 | 2001-07-01 | 2006-01-09 |
| NCT01231165 | Coronary Heart Disease | Drug: Amiloride|Drug: Nitrates, clopidogrel, aspirin, statins | University of Carabobo|Clinical Research Unit at the Docent Institute of Urology|Northern Metropolitan Hospital|Venezuelan Foundation of Heart Failure | Phase 2|Phase 3 | 2009-02-01 | 2012-06-08 |
| NCT00285805 | Insulin Resistance | Drug: Rosiglitazone versus placebo|Drug: response (sodium excretion) to amiloride infusion|Drug: response (sodium excretion) to furosemide infusion | Radboud University | | 2006-02-01 | 2010-08-23 |
| NCT01388088 | Hypertension | Drug: Spironolactone|Drug: Amiloride|Drug: Placebo | Erling Bjerregaard Pedersen|Regional Hospital Holstebro | Phase 4 | 2010-09-01 | 2012-03-27 |
| NCT01195805 | Essential Hypertension | Drug: Spironolactone|Other: Placebo|Drug: Amiloride | Regional Hospital Holstebro | | 2010-08-01 | 2015-08-19 |
| NCT00394394 | Hypertension | Drug: Amiloride 2,5/d or Enalapril/d 10 mg | Hospital de Clinicas de Porto Alegre | Phase 2 | 2005-02-01 | 2006-10-30 |
| NCT01804777 | Proteinuria|Hypertension|Type II Diabetes | Drug: Amiloride|Drug: HCTZ | University of New Mexico|Dialysis Clinic, Inc.|University of Pittsburgh | Early Phase 1 | 2013-03-01 | 2014-09-26 |
| NCT01095133 | Gastroesophageal Reflux Disease|Heartburn | Drug: Amiloride|Drug: Placebo | University of North Carolina, Chapel Hill | Phase 1 | 2010-03-01 | 2012-09-18 |
| NCT01918488 | Diabetic Nephropathies|Hypertension | Dietary Supplement: Standardized salt diet|Drug: Amiloride | University of Southern Denmark|Odense University Hospital|Region of Southern Denmark|The Ministry of Science, Technology and Innovation, Denmark|Danish Heart Foundation | | 2013-10-01 | 2013-10-14 |
| NCT00857909 | High Blood Pressure | Drug: Amiloride|Drug: Spironolactone|Drug: Placebo|Drug: Placebo and spironolactone|Drug: Spironolactone | Regional Hospital Holstebro | Phase 1 | 2009-01-01 | 2011-07-07 |
